Female pattern hair loss

Hair, Hair Growth and Hair Disorders

Volumn , Issue , 2008, Pages 171-186

  Olsen, Elise A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 63049098408     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-46911-7_10     Document Type: Chapter

References (114)

1. Agarwal SK, Hughes CL, Hirsutism In Olsen EA (Ed) (2004) Disorders of Hair Growth: Diagnose and Treatment. McGraw-Hill, NY.
2. Aram H (1979) Treatment of female androgenetic alopecia with cimetidine. Gastroenterology; 76: 504-508.
3. Assiz R, Sanchez A, Knochenhauer ES, et al (2004) Androgen excess in women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metab; 89: 453-462.
4. Avram MR, Cole JP, Gandelman M, et al (2002) The potential role of minoxidil in the hair transplanting setting. J Dermatol Surg; 28: 10: 894-900.
5. Barman JM, Pecoraro V, Astore I (1969) Biological basis of the inception and evolution of baldness. J Gerontol; 24: 163-168.
6. Beek CH (1950) A study on extension and distribution of the human body-hair. Dermatologica; 101: 317-331.
7. Bingham KD, Shaw DA (1973) The metabolism of testosterone by human male scalp hair. J Endocrinol; 57; 811-819.
8. Birch MP, Messenger JF, Messenger AG (2001) Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol; 144: 297-304.
9. Birch MP, Lashen H, Agarwal S et al (2006) Female pattern hair loss, sebum excretion and the end-organ response to androgens. Br J Dermatol; 154: 85-89.
10. Burke BM, Cunliffe WJ (1985) Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia [Letter]. Br J Dermatol; 112: 124-125.
11. Camacho F (2001) Hissutismo: Enfoque dclinico terapeutico. Act Terap Dermatol; 24: 190-206.
12. Cameron DR, Braunstein GD (2004) Androgen replacement therapy in women. Fertil Steril; 82: 273-289.
13. Carey AH, Waterworth D, Patel K, et al (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet; 3: 1873-1876.
14. Carmina E, Lobo RA (2003) Treatment of hyperandrogenic alopecia in women. Fertil Steril; 79: 91-95.
15. Cela E, Robertson C, Rush K, et al (2003) Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol; 149: 439-442.
16. Chen WC, Thiboutot D, Zouboulis CC (2002) Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol; 119: 992-1007.
17. Choi MH, Yoo YS, Chung BC (2001) Biochemical roles of testosterone and epitestosterone to 5α-reducatase as indicators of male-pattern baldness. J Invest Dermatol; 116: 57-61.
18. Conrad F, Paus R (2004) Ostrogene und der Haarfollikel. JDDG; 2: 412-423.
19. Conrad F, Ohnemus U, Bodo E, et al (2004) Estrogens and human scalp hair growth - still more questions than answers. J Invest Dermatol; 122: 840-842.
20. Corvol P, Michaud A, Menard J, et al (1975) Antiandrogenic effect of spironolactone: mechanism of action. Endocrinology; 97: 52-58.
21. Courtois M, Loussouvn G, Hourseau C, et al (1995) Ageing and hair cycles. Br J Dermatol; 132: 86-93.
22. Cusan L, Dupont A, Gomez JL, et al (1990) Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol; 23: 462-469.
23. Cusan L, Dupont A, Gomez JL, et al (1994) Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil Steril; 61: 281-287.
24. Dawber RPR, Sonnex T, Ralfs I. (1982) Oral anti-Androgen treatment of common baldness in women. Br J Dermatol; 107 (suppl 22):20.
25. Deloche C, de Lacharriere O, Misciali C, et al (2004) Histological features of peripilar signs associated with androgenetic alopecia. Arch Dermatol Res; 295(10): 422-428.
26. DeVillez RL, Jacobs JP, Szpunar CA, et al (1994) Androgenetic alopecia in the female: Treatment with 2% topical minoxidil solution. Arch Dermatol; 30: 303-307.
27. Drake LD, Hordinsky M, Fiedler V, et al (1999) The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol; 41: 550-554.
28. Ekoe JM, Burkhardt P, Ruedi B (1980) Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica; 160: 398-404.
29. Ferry JJ, Turner SW, Albert DG, et al (1996) Hemodynamic effects of minoxidil following intravenous infusion in untreated hypertensive patients. Clin Pharmacol Ther; 59: 166.
30. Fischer TW, Burmeister G, Schmidt HW et al (2004) Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: Results of a pilot randomized controlled trial. Br J Dermatol; 150: 341-345.
31. Futterweit W, Dunaif A, Yeh H-C, et al (1988) The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol; 19: 831-836.
32. Gan DCC, Sinclair RD (2005) Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc; 10: 184-189.
33. Gassmueller J, Hoffmann R, Webster A (2007) A treatment of androgenetic alopecia using topical fulvestrant solution in males and post-meonopausal females. Poster presentation at European Hair Research Society meeting, London, Great Britain, June 2007.
34. Gomez JL, Dupont A, Cusan L, et al (1992) Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med; 92: 465-470.
35. Goss PE, Ingle JN, Martino S, et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med; 349: 1793-1802.
36. Guerrera M, Ciulla MP (1986) A quantitative evaluation of hair loss: The phototrichogram. J Appl Cosmetol; 4: 61-66.
37. Guerrera M, Rebora A (1996) Anagen hairs may fail to replace telogen hairs in early androgenic female alopecia. Dermatology; 192: 28-31.
38. Hamilton JB (1942) Male hormone stimulation is prerequisite to an incite in common baldness. Am J Anat; 71: 451-452.
39. Hamilton JB (1951) Patterned loss of hair in man: Types and incidence. Ann NY Acad Sci; 53: 708-728.
40. Hammerstein J, Meckies J, Leo-Rossberg I, et al (1975) Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism or virilism. J Steroid Biochem; 6: 827-836.
41. Hoffmann R, Rot A, Niiyama S, et al (2001) Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. J Invest Dermatol; 117(6): 1342-1348.
42. Iorizzo M, Vincenzi C, Voudouris S, et al (2006) Finasteride treatment of female pattern hair loss. Arch Dermatol; 142: 298-302.
43. Jackson D, Church RE, Ebling FJ (1972) Hair diameter in female baldness. Br J Dermatol; 87: 361-367.
44. Jacobs JP, Szpunar CA, Warner ML (1993) Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol; 32: 758-762.
45. Kaufman KD, Olsen EA, Whiting D, et al (1998) Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol; 39:578-589.
46. Kossard S (1994) Postmenopausal frontal fibrosing alopecia. Arch Dermatol; 130: 770-774.
47. Labrie F, Luu-The V, Labrie C, et al (2000) Intracrinology and the skin. Hormone Res 2000; 54: 213-229.
48. Lobo RA, Shoupe D, Serafini P, et al (1985) The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril; 43: 200-205.
49. Lucky AW, Piacquadio DJ, Ditre CM, et al (2004) A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol; 50: 541-553.
50. Ludwig E (1964) Die androgenetische alopecie bei der Frau. Arch Klin Exp Dermatol; 219: 558.
51. Ludwig E (1977) Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol; 97: 247-254.
52. Maguire HC Jr, Kligman AM (1963) Common baldness in women. Geriatrics; 18: 329-334.
53. Mansouri P, Mortazavi M, Eslami M et al (2005) Androgenetic alopecia and coronary artery disease in women. Dermatol Online J; 11(3): 2.
54. Messenger AG, Rundegren J (2004) Minoxidil: Mechanisms of action on hair growth. Br J Dermatol; 150: 186-194.
55. Mortimer CH, Rushton H, James KC (1984) Effective medical treatment for common baldness in women. Clin Exp Dermatol; 9: 342-350.
56. Niiyama S, Happle R, Hoffmann R (2001) Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol; 11: 195-198.
57. Norwood OT (2001) Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg; 27: 53-54.
58. Oh H-S, Smart RC (1996) An estrogen receptor pathway regulates the telogen-Anagen hair follicle transition and influences epidermal cell proliferation. Proc Natl Acad Sci; 93: 12525-12530.
59. Olsen EA (1994) Androgenetic alopecia. In: Olsen EA (Ed) (1994) Disorders of Hair Growth: Diagnosis and Treatment. New York: McGraw-Hill; p. 257-283.
60. Olsen EA (1994) Clinical tools for assessing hair loss. In Olsen EA (Ed) (1994) Disorders of Hair Growth: Diagnosis and Treatment. New York: McGraw-Hill; p. 59-69.
61. Olsen EA (1999) The midline part: An important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol; 40: 106-109.
62. Olsen EA (2001) Female pattern hair loss. J Am Acad Dermatol; 45: S70-S80.
63. Olsen EA (2003) Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol; 48: 253-262.
64. Olsen EA (2004) Pattern hair loss in men and women, in Olsen EA (Ed) Hair Disorders: Diagnosis and Treatment. McGraw-Hill, NY.
65. Olsen EA (2005) Female pattern hair loss and its relationship to permanent/cicatricial alopecia: A new perspective. J Investig Dermatol Symp Proc; 10(3): 217-221.
66. Olsen EA, Weiner MS (1987) Topical minoxidil in male pattern baldness: Effect of discontinuation of treatment. J Am Acad Dermatol; 17: 97-101.
67. Olsen EA, Weiner MS, DeLong ER, et al (1985) Topical minoxidil in early male pattern baldness. J Am Acad Dermatol; 13: 185-192.
68. Olsen EA, Bergfeld W, Cotsarelis G, et al (2003) Summary of NAHRS-sponsored workshop on cicatricial alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol; 48:103-110.
69. Olsen EA, Messenger AG, Shapiro J, et al (2005) Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol; 52: 301-311.
70. Olsen EA, Hordinsky M, Whiting D, et al (2006) The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol; 55: 1014-1023.
71. Olsen EA, Whiting D, Bergfeld W, et al (2007) A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam vs placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol; 57(5): 767-774.
72. Olszewska M, Rudnicka L (2005) Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol; 4: 637-640.
73. Orfanos CE, Vogels L (1980) Lokaltherapie der Alopecia Androgenetica mit 17a -Ostradiol. Dermatologica; 161: 124-132.
74. Orme S, Cullen DR, Messenger AG (1999) Diffuse female hair loss: Are androgens necessary? Br J Dermatol; 141: 521-523.
75. Park JH, Yoon JB, Sim WY, et al (2001) The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol; 145: 95-99.
76. Peereboom-Wynia JD, van der Willigen AH, van Joost T, et al (1989) The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Dermatol Venereol; 69: 395-398.
77. Price VH, Roberts JL, Hordinsky M, et al (2000) Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol; 43 (5 Pt 1): 768-776.
78. Puerto AM, Mallol J (1990) Regional scalp differences of the androgenetic metabolic pattern in subjects affected by male pattern baldness. Rev Esp Fisiol; 46: 289-286.
79. Riggs BL, Hartmann LC (2003) Seletive estrogen-receptor modulators - mechanism of action and application to clinical practice. N Engl J Med; 348: 618-629.
80. Roberts JL, Fielder V, Imperato-McGinley J, et al (1999) Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol; 41:555-563.
81. Rushton DH, Ramsay ID (1992) The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen- dependent alopecia in women. Clin Endocrinol; 36: 421-424.
82. Rushton DH, Futterweit W, Kingsley DH, et al (1991) Quantitative assessment of spironolactone treatment of women with diffuse androgen-dependent alopecia. J Soc Cosmet Chem; 42: 317-325.
83. Sawaya ME, Price VH (1997) Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol; 109: 296-300.
84. Schmidt HB, Lindmaier A, Trenz A, et al (1991) Hormone studies in females with androgenic hairloss. Gynecol Obstet Invest; 31: 235-239.
85. Schweikert HU, Wilson JD (1974) Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J Clin Endocrinol Metab 38: 811-819.
86. Sciarra F, Toscano V, Concolino G, et al (1990) Antiandrogens: clinical applications. J Steroid Biochem Mol Biol; 37: 349-362.
87. Shum KW, Cullen DR, Messenger AG (2002) Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol; 47: 733-739.
88. Sinclair R (2004) The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. J Am Acad Dermatol; 51: 189-199.
89. Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol; 152: 466-473.
90. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med; 348: 2431-2442.
91. Smith MA, Wells RS (1964) Male-Type alopecia, alopecia areata and normal hair in women: family histories. Arch Dermatol; 89: 95-98.
92. Thai K-E, Sinclair RD (2002) Finasteride for female androgenetic alopecia. Br J Dermatol; 147: 808-840.
93. Thornton MJ (2002) The biological actions of estrogens on skin. Exp Dermatol; 11: 487-502.
94. Tindll DJ, Chang CH, Lobl TJ, et al (1984) Androgen antagonists in androgen target tissues. Pharmacol Ther; 24: 367-400.
95. Tremblay RR (1986) Treatment of hirsutism with spironolactone. Clin Endocrinol Metab; 15: 363-371.
96. Trost LB, Bergfeld WF, Calgeras E (2006) The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol; 54: 824-844.
97. Trueb RM (2004) Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology; 209: 202-207.
98. Ueki R, Tsuboi R, Inaba Y, et al (2003) Phototrichogram analysis of Japanese female subjects with chronic diffuse hair loss. J Investig Dermatol Symp Proc; 8: 116-120.
99. Unger WP, Hair transplantation in females. In: Unger WP (ed) (1988) Hair Transplantation. Dekker, New York, pp. 295-300.
100. Unger WP, Unger RH (2003) Hair transplanting: An important but often forgotten treatment for female pattern hair loss. J Am Acad Dermatol; 49: 853-860.
101. Uno H, Cappas A, Schlagel C (1985) Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of stumptailed macaques. Am J Dermatopathol; 7: 283-297.
102. Valsecchi R, Leghissa P, Riva M (2004) Female androgenetic alopecia treated by finasteride: A case forward. Acta Derm Venereol; 84: 488-489.
103. Vanwayjen RG, Van den Ende A (1995) Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate containing preparations: Efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes; 103: 241-251.
104. Venning VA, Dawber RPR (1988) Patterned androgenic alopecia in women. J Am Acad Dermatol; 18: 1073-1077.
105. Vexiau P, Chaspoux C, Boudou P, et al (2002) Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: A controlled, 12-month randomized trial. Br J Dermatol; 146: 992-999.
106. Vierhapper H, Nowotny P, Maier H, et al (2001) Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab; 86: 5752-5764.
107. Vierhapper H, Maier H, Nowotny P, et al (2003) Production rates of testosterone and dihydrotestosterone in female pattern hair loss. Metabolism; 52: 927-929.
108. Whiting DA (1993) The diagnostic and predictive value of horizontal sections of scalp biopsies in male pattern androgenetic alopecia. J Am Acad Dermatol; 28: 755-763.
109. Whiting DA (1996) Chronic telogen effluvium: increased scalp hair shedding in middle-Aged women. J Am Acad Dermatol; 35: 899-906.
110. Whiting DA (1998) Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia. Dermatol Ther; 8: 24-33.
111. Whiting DA, Waldstreicher J, Sanchez M, et al (1999) Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies. Results of finasteride 1 mg treatment of men and postmenopausal women. J Invest Dermatol Symp Proc; 4: 282-284.
112. Yasmin (2007) Physician's Desk reference; 61: 796-803.
113. Zajac JD (2003) Women, androgens and skin (abstract). Exp Dermatol; 12: 224.
114. Zinkernagel MS, Trueb RN (2002) Fibrosing alopecia in a pattern distribution: patterned lichen planopilaris or androgenetic alopecia with a lichenoid tissue reaction pattern? Arch Dermatol; 135: 205-211.